ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Alpha-2 Agonist — Rosacea Erythema Pregnancy: Avoid — limited data; minimal systemic absorption with topical use; azelaic acid preferred for rosacea in pregnancy

Brimonidine Gel (Topical)

Brand names: Mirvaso

Adult dose

Dose: 0.5% gel — apply a pea-sized amount to each of 5 facial areas (forehead, chin, nose, each cheek)
Route: Topical
Frequency: Once daily
Max: Once daily application
Selective alpha-2 adrenergic agonist for persistent facial erythema of rosacea (subtype 1 — erythematotelangiectatic). Causes dermal vasoconstriction. Onset 30 minutes; duration 8–12 hours. Does not treat papules/pustules — use metronidazole or ivermectin for those. On-demand use possible.

Paediatric dose

Dose: Not applicable topical/kg
Route: Topical
Frequency: Once daily
Max: Not established in children
Not licensed in children — rosacea is predominantly adult. Avoid in children.

Dose adjustments

Renal

No dose adjustment required (topical — minimal systemic absorption)

Hepatic

No dose adjustment required

Paediatric weight-based calculator

Not licensed in children — rosacea is predominantly adult. Avoid in children.

Clinical pearls

  • Treats erythema only — has NO effect on papules, pustules, or telangiectasia; combine with metronidazole or ivermectin for papulopustular rosacea
  • Rebound erythema: significant limitation — as vasoconstriction wears off, rebound vasodilation can produce worse erythema than baseline; use intermittently to manage this
  • Apply sparingly — avoid eyes, lips, and mucous membranes; wash hands after application
  • MHRA: rare cases of aggravated erythema, flushing, and burning reported — monitor response carefully; if worsening, discontinue
  • Laser/IPL (intense pulsed light) therapy is the most effective treatment for persistent erythema and telangiectasia in rosacea — brimonidine is a medical alternative
  • Oxymetazoline 1% cream (Rhofade) is an alternative alpha-agonist for rosacea erythema — similar mechanism, not yet widely available in UK

Contraindications

  • Hypersensitivity to brimonidine
  • Age <2 years (systemic alpha-2 agonist risks in infants)
  • Sjogren's syndrome (reduced tear production — risk of dry eye exacerbation)

Side effects

  • Rebound erythema/flushing (most clinically significant — worsening after gel wears off)
  • Local skin irritation
  • Pruritus
  • Skin dryness
  • Paradoxical worsening in some patients
  • Systemic alpha-2 agonist effects (rare — dizziness, bradycardia, hypotension if large area)

Interactions

  • MAOIs — systemic alpha-2 agonist interaction (avoid)
  • Antihypertensives — additive hypotension (minimal with topical use)
  • Cardiac glycosides — potential additive bradycardia (minimal topically)

Monitoring

  • Facial erythema response at 4 weeks
  • Rebound erythema after application wears off
  • Systemic effects (BP, pulse) if large area use

Reference: BNFc; BNF 90; Fowler et al. (2012) J Drugs Dermatol Brimonidine rosacea; BAD Rosacea Guidelines 2017; NICE CKS Rosacea; SPC Mirvaso. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways